The standard treatment of HCV infection with pegylated interferon-a2a or -a2b and ribavirin is effective in <50% of HCV genotype-1-infected patients. To improve this figure, it might be desirable to obtain optimal plasma concentrations of the drug by increasing the dose. Unfortunately, there is great interpatient variability in ribavirin pharmacokinetics. In the present review, we describe the mechanism of ribavirin-induced anaemia in detail, evaluate host predictive factors for this harmful side effect and assess the literature data on attempts to improve the sustained virological response rate by increasing the dose of ribavirin. We suggest an optimal steady-state concentration range for ribavirin in monoinfected and coinfected patients. Lastly, we propose that it would be of particular value to monitor ribavirin concentrations in HCV genotype-1-infected patients and (regardless of the genotype) coinfected patients, haemodialyzed patients and obese patients.
In Europe, between 8 and 10 million individuals currently suffer from chronic HCV infection. It is expected that over the next [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] years, approximately 20% of these individuals will develop complications such as cirrhosis, and will ultimately require liver transplantation [1] . The current recommended therapy for chronic HCV infection is a combination of pegylated interferon (PEG-IFN)-a and ribavirin. For HCV genotype 1 and 4 infections, treatment with PEG-IFN-a plus ribavirin should last for 48 weeks. The dose for PEG-IFN-a2a is 180 µg per week (injected subcutaneously), together with ribavirin at a dose of 1,000 and then 1,200 mg/day. The dose for subcutaneous injection of PEG-IFN-a2b is 1.5 µg/kg per week, together with ribavirin at doses ranging from 800 to 1,400 mg/ day as a function of body weight (BW) [2] . For genotype 2 and 3 infections, treatment with PEG-IFN-a plus ribavirin (at a dose of 800 mg/day) should be administered for 24 weeks. Combination therapy with PEG-IFN-a and ribavirin is effective in approximately 80% of patients infected with genotype 2 or 3, but <50% of those infected with genotype 1 HCV.
Several predictive factors have been linked to a better treatment outcome and can be grouped into three categories in relation to the host (young age, non-African-American ethnicity, male gender, low body mass index and lack of insulin resistance), liver status (increased alanine aminotransferase levels and no or minimal hepatic fibrosis) and the treatment modality (use of optimal doses of PEG-IFN-a and/or ribavirin, a sufficiently long treatment duration and good compliance) [3] . The main predictive factors of a poor sustained virological response (SVR) are infection with an HCV genotype other than 2 or 3, a high baseline viral load and a ribavirin dose <10.6 mg/kg BW/day [4] .
Good compliance with combination therapy has been shown to enhance the SVR in genotype-1-infected patients with chronic hepatitis C [5] ; therefore, the development of strategies for maximizing compliance is an important issue. Achievement of a good SVR results from three independent steps: the initial achievement of a virological response, maintenance of the response and avoidance of relapse. Ribavirin plays a role in all three steps; however, current ribavirin dose recommendations are solely based on the patient's BW.
The efficacy of ribavirin varies widely from one individual to another, despite apparently low observed Introduction intraindividual variations in plasma ribavirin concentrations. The aim of personal ribavirin therapeutic monitoring is to adjust an individual's dose and to increase the probability of achieving an SVR with acceptable side effects. Monitoring the concentrations of antiretroviral drugs has been beneficial in the clinical management of patients infected with HIV and has improved virus suppression while minimizing toxicity [6] . The establishment of a therapeutic window for ribavirin levels (defined as the concentration range associated with an optimal efficacy/toxicity ratio) might be of great value in the appropriate use of this drug.
Relationships between plasma ribavirin concentrations and pharmacodynamics have already been reported (both in terms of activity and toxicity); the haemoglobin nadir corresponding to dose-limiting toxicity was inversely associated with the ribavirin concentration [7] and higher ribavirin concentrations were associated with a higher antiviral response rate [8, 9] . Anaemia is a frequent, dose-dependent, limiting side effect of ribavirin use; therefore, personal monitoring of plasma ribavirin concentrations could be a useful tool for individualizing HCV treatment.
The present article reviews the current approaches to optimizing ribavirin monitoring. After conducting a review of ribavirin's mechanism of action and adverse effects, we focused on ribavirin's haemolysis and determined the predictive factors of anaemia. We have proposed practice guidelines to optimize treatment efficacy by monitoring ribavirin concentration or doses.
Ribavirin's mechanism of action
Many hypotheses for ribavirin's mechanism of action have been reported, suggesting that only a pleiotropic effect can explain the drug's overall activity. Because ribavirin is a nucleoside analogue, its incorporation into the viral genome can lead to mutagenesis [10] [11] [12] . The ability of ribavirin to base pair with both cytidine and uridine suggests that ribavirin should increase the frequency of transition mutations in the viral genome and also force the virus into an 'error catastrophe'. Ribavirin has also been shown to competitively inhibit the activity of the intracellular enzyme inosine monophosphate dehydrogenase; this leads to depletion of cellular guanosine triphosphate pools and inhibition of the replication of several flaviviruses and paramyxoviruses (at least in vitro) [13] .
Hultgren et al. [14] have reported an immunosuppressive effect of ribavirin and a shift in the T-helper (Th)-1/Th-2 balance in HCV-specific immune responses. Other mechanisms of action have been proposed, including the inhibition of viral polymerase activity [15] and, most recently, modulation of IFN-stimulated gene expression [16] .
Ribavirin's adverse effects
Almost all patients treated with PEG-IFN-a and ribavirin experience one or more adverse events during the course of therapy. Indeed, these events often cause patients to reduce or stop therapy. With regard to ribavirin, the most common side effect is haemolytic anaemia. Anaemia is frequently observed in patients receiving the drug in combination with standard IFN or PEG-IFN-a [4] and is the most common reason for therapy discontinuation. Other potential side effects of ribavirin are nausea, skin problems and respiratory disorders. Because ribavirin is cleared by the kidney, the drug should be used with extreme caution in patients with renal disease or failure [17] .
The mechanism of ribavirin-induced haemolytic anaemia
Although haemolytic anaemia is commonly associated with ribavirin combination therapy, the extent of the condition can vary greatly from one individual to another. Severe ribavirin-induced anaemia can increase fatigue and worsen quality of life and is, therefore, a frequent indication for ribavirin discontinuation or dose reduction. Efforts to minimize ribavirin-induced haemolytic anaemia also include dose reduction and the use of erythropoietin (EPO). Although both approaches might be effective, the former might compromise the antiviral response and the latter often requires weeks to take effect and is costly.
It is widely assumed that ribavirin-induced anaemia primarily results from increased red blood cell (RBC) turnover. Ribavirin concentrates in circulating RBCs [18, 19] and causes a relative ATP deficiency and increased susceptibility to oxidative damage [20] .
Once ribavirin enters the RBC via the equilibrative nucleoside transporter 1, the drug is converted into the corresponding triphosphate form. The accumulation of ribavirin triphosphate is probably caused by the RBC's lack of the 5′-nucleotidases and alkaline phosphatases, which hydrolyze ribavirin phosphates in nucleated cells [21] . Because phosphorylated ribavirin cannot be exported from RBCs, it accumulates and reaches concentrations that are approximately 50-100-fold higher than in plasma. This produces a relative intra-RBC ATP deficiency [19, 22] , which might indirectly affect oxidative stress defence mechanisms by decreasing the hexokinase-mediated production of glucose 6-phosphate (a key common substrate for glycolysis and the pentose phosphate shunt). The combination of these pro-oxidant events might induce premature RBC senescence. Furthermore, the extracellular oxidative stress related to HCV infection itself might also play a contributory role in ribavirin-induced membrane changes in predisposed RBCs that have already up-regulated their antioxidant defences [23] .
When ribavirin is used as a monotherapy, rapid reticulocytosis compensates for the haemolysis and the decrease in haemoglobin levels (∆Hb) is approximately 1 g/dl [24] ; however, when IFN or PEG-IFN-a is combined with ribavirin, the bone marrow response to haemolysis is suppressed and a significantly greater mean ∆Hb (2.5-3 g/dl) is then observed. Indeed, nearly 20% of patients show a ∆Hb of >4 g/dl. Haemoglobin levels start to decrease soon after beginning therapy and decrease quickly until week 4, when they then show a slower decrease until the beginning of week 8. This decrease is a function of the pharmacokinetics of ribavirin, which depends on the renal function of the patient.
In a study of 832 treatment-naive patients with chronic HCV infection, the maximum ∆Hb was 2.9 g/dl after 24 weeks of therapy. The decrease began after 1 week and stabilized after 4 weeks of therapy. Reticulocyte counts increased and reached a peak at 4 weeks [25] . Following the cessation of therapy, haemoglobin concentrations and reticulocyte counts returned to pretreatment levels after a further 3-10 weeks. In approximately 10% of the patients, haemoglobin levels decreased to below 10 g/dl, requiring ribavirin dose reductions and potentially endangering the chances of an SVR [26] . Saito et al. [27] identified a number of factors that are associated with ribavirin discontinuation: female gender, low initial haemoglobin concentration, low creatinine clearance, low apparent ribavirin clearance and high serum ribavirin concentrations at 1 week. Predictors of the risk of developing anaemia include older age, female gender, low platelet counts and low BW [26, 28] .
In total, two studies have used alveolar carbon monoxide measurements to calculate the lifespan of RBCs in HCV-infected patients undergoing ribavirin treatment. Krishnan and Dixit [29] and Virtue et al. [30] estimated the mean RBC lifespan ±sd to be 46 ±14 days and 39 ±13 days, respectively. This indicates that ribavirin affects RBC survival [29, 30] because in HCV-infected patients not undergoing treatment with ribavirin, the same groups reported mean lifespans ±sd of 107 ±22 days and 112 ±17 days, respectively, with good agreement between the two studies.
In HCV patients coinfected with HIV, ribavirinassociated anaemia is an even greater problem [31] . The condition is especially common and severe in individuals taking azidothymidine [32] . Moreover, because ribavirin inhibits inosine-5-monophosphate dehydrogenase, the toxicity of didanosine is accentuated. Indeed, it has been suggested that ribavirin should not be used in individuals receiving these drugs [33] . Lastly, antiretroviral drugs might affect the response to HCV through inhibitory competition phenomena between ribavirin and certain nucleoside analogues. This might be the reason for the frequently reported association between abacavir use and low SVR rates. Because both drugs are guanosine analogues and share intracellular phosphorylation pathways, competition for the same enzymes might interfere with their respective antiviral activities [34] .
Predicitive factors for anaemia
Many publications have addressed this subject. Oze et al. [35] and Nomura et al. [23] proposed that 2 g/ dl ∆Hb after 2 weeks of treatment should be adopted as a predictive factor for progression to severe anaemia (the '2 by 2' rule). A significant relationship between the rate of ∆Hb at week 2 and the severity of anaemia has been observed. Reau et al. [36] have suggested that an early ∆Hb of >1.5 g/dl after just 2 weeks of therapy is predictive of a larger decrease (>2.5 g/dl) by week 4. Hung et al. [26] have shown that pretreatment platelet counts (<150,000 platelets/mm 3 ), older age (>50 years), female gender and low BW (<65 kg) independently contributed to the risk of severe anaemia. Reau et al. [36] have advocated that certain parameters should be closely monitored for anaemia, including age (an increased risk with every 10-year increase), low baseline haemoglobin (an increased risk with every 1 g/dl decrease) and low creatinine clearance (an increased risk with every 10 ml/min decrease).
In a study by Van Vlierberghe et al. [28] , the influence of 17 variables on ∆Hb during a 4-week course of treatment with IFN-a2b and ribavirin was examined. In the overall patient population, the mean ±sd ∆Hb was 2.5 ±1.4 g/dl. Only six of the variables had a statistically significant correlation with ∆Hb in a univariate analysis: gender, pretreatment haemoglobin level, pretreatment platelet count, pretreatment uric acid level, treatment and haptoglobin phenotype. Patients with a higher pretreatment haemoglobin level had a higher ∆Hb; however, when the ∆Hb was expressed as a percentage of the pretreatment haemoglobin levels, the decrease was the same in both cases. This finding prompted the researchers to suggest that the ribavirin-induced haemolysis breaks down a certain proportion of the available RBC pool (approximately 17%). Moreover, Van Vlierberghe et al. [28] have shown that ∆Hb was smaller in patients with higher platelet counts (>110,000 platelets/mm 3 ) and those not bearing a haptoglobin 1-1 phenotype.
In a study on a cohort of 30 HCV-infected patients, Grattagliano et al. [37] have shown that patients with severe haemolysis (∆Hb>6 g/dl [five patients]) had lower median pretreatment values of membrane protein sulfhydryl (PSH) groups on RBCs than patients with minor haemolysis (∆Hb<2.5 g/dl [25 patients]). All patients with a pretreatment PSH concentration <32 nmol/mg protein developed severe ribavirinassociated haemolysis. The RBC PSH concentration was not only a predictor of major haemolysis but also differentiated between healthy controls and hepatitis C patients. Given that membrane PSHs play an important role in membrane fluidity and deformability, the lower PSH concentration found in haemolytic patients might increase the fragility of RBCs and make the latter more susceptible to haemolysis during administration of ribavirin. This effect might be additive with the oxidative stress caused by HCV infection.
The dose-response relationship

Monoinfected patients
McHutchison et al. [5] have reported that the total ribavirin dose received during the first 12 weeks of treatment was predictive of the SVR. An interesting paper by Jacobson et al. [2] observing weight-based dosing of PEG-IFN-a2b and ribavirin (WIN-R) notably compared the SVR in 362 African-Americans infected with genotype 1 HCV. The patients were treated with PEG-IFN-a plus either 800 mg/day ribavirin in a 'flat' ribavirin arm or between 800 and 1,400 mg/day in the weight-based-dosing arm. The SVR rates were higher in the weight-based-dose group than in the flat-dose group (21% versus 10%, respectively) and relapse rates were lower (22% versus 30%, respectively). Safety and drug discontinuation rates were similar in the two groups. In a report on the WIN-R trial with 5,000 patients of all HCV genotypes, Jacobson et al. [9] showed that the SVR (but not the end-of-treatment response) was significantly higher with weight-based ribavirin than with flat-dose ribavirin (44.2% versus 40.5%; P<0.008). In genotype-2-and 3-infected patients, the rates were not significantly different (61.8% and 59.5%, respectively). Interestingly, the authors stated that weight-based dosing of ribavirin at a dose of 800-1,400 mg/day (when combined with PEG-IFN-a2b 1.5 µg/kg/week) removed BW as a factor influencing response in patients infected with genotype 1 (the most difficult to treat and most prevalent genotype). They agreed on the superiority of weight-based ribavirin dosing in IFN combination treatments of genotype-1-infected patients.
A study performed by Manns et al. [4] on 1,530 patients showed that gender and weight were no longer significant response factors when the dose of ribavirin was expressed as mg/kg. Because women tended to weigh less than men and therefore receive higher doses of ribavirin per unit of BW, the former presented a better treatment response.
Snoeck et al. [7] have pooled the data from two studies [38, 39] of patients (1,732 in total) treated with PEG-IFN-a2a plus ribavirin. For genotype-1-infected patients, the probability of an SVR was found to increase from approximately 40% to 54% when the ribavirin dose was increased from 12 to 16 mg/kg/day. By contrast, the probability of an SVR in genotype-2-and 3-infected patients does not appear to be strongly correlated with the ribavirin dose/kg. The overall SVR in patients infected with genotypes 2 or 3 was approximately 81%, implying that a low dose of ribavirin (800 mg/day) is as effective as the higher, standard dose (1,000 or 1,200 mg/day) in these patients with a lower risk of anaemia; thus for genotypes 2 and 3, the increase in the dose of ribavirin per day seems not to be of any interest. Nevertheless, the dose of ribavirin seems to be important for shortened treatment [40] . Moreover, the clinical studies, including both genotype-2-and 3-infected patients, have shown a different response rate between these two genotypes [41, 42] ; therefore, perhaps ribavirin dose could be important for the treatment of HCV genotype 3 infection.
Coinfected patients
In HIV-HCV-coinfected patients, the risk of drug interactions between antiretroviral drugs and ribavirin might increase toxicity and compromise the virological response. Successful treatment outcomes are substantially rarer in coinfected patients than in monoinfected ones. Studies in HIV-HCV-coinfected patients have shown a mean SVR rate of 17-62% (17-29% for genotypes 1 or 4 and 44-62% for genotypes 2, 3 and 5) [43] . The response to therapy is generally slower in coinfected patients. Most coinfected patients are treated with PEG-IFN-a and fixed low doses (800 mg/ day) of ribavirin. It is unclear whether HIV itself and/ or suboptimal ribavirin dose exposure can explain this poorer outcome. A comparison of two trials in coinfected patients treated with PEG-IFN-a and ribavirin highlights the importance of ribavirin. In the PRESCO multicenter trial, Núñez et al. [44] used high ribavirin doses (1,000 mg/day if BW<75 kg and 1,200 mg/day if BW>75 kg) in 384 patients. The overall SVR was 49.6%, with 35.6% for a subgroup of 191 genotype-1-infected patients. In the APRICOT trial [43] (in which low-dose ribavirin [800 mg/day] was used), the SVR was 28% for genotype-1-infected patients in general and 18% in genotype-1-infected patients with a high viral load. In the RIBAVIC study, Carrat et al. [45] reported an SVR rate of 17% in genotype-1-infected patients treated with PEG-IFN-a and 800 mg/day ribavirin. Thus, prescription of high-dose ribavirin enhances the early HCV treatment response in HCV-HIV-coinfected patients, with results similar to those described in HCV-monoinfected patients; however, the high rates of treatment discontinuation (related to drug side effects) observed in most trials with coinfected patients could also explain this much poorer outcome.
As there is great interindividual variability in the pharmacokinetics of ribavirin, in particular for the elimination phase, the use of ribavirin according to body weight is not optimal. Ribavirin clearance is strongly dependent on renal function. This explains the suggestion of Bruchfeld et al. [46] that the practice of dosing ribavirin on the basis of BW only, as is currently recommended, is invalid, and the dose must instead be determined using knowledge of renal function.
The relationship between serum ribavirin concentration and response
Monoinfected patients
Lindahl et al. [47] have proposed that a plasma ribavirin concentration >15 µM (3.67 µg/ml) might improve the response rate in genotype 1 infections. Indeed, this hypothesis was tested on 10 genotype-1-infected patients treated with a high enough dose of ribavirin to meet this target concentration. An SVR was obtained in nine patients but all received EPO. Moreover, Arase et al. [8] measured ribavirin levels at week 8 in 68 genotype-1-infected patients. The SVR rates increased in proportion to ribavirin levels at week 8 and the overall SVR was 25%. For patients with a serum ribavirin concentration <2.5 µg/ml (10.23 µM) at week 8, the SVR was 14.8%; between 2.5 and 3 µg/ ml (10.23-12.28 µM) the SVR was 25%; between 3 and 3.5 µg/ml (12.28-14.33 µM) the SVR was 44.4% and at >3.5 µg/ml the SVR was 42.9%. The frequency of treatment dropout in patients with a serum ribavirin concentration of >3.5 µg/ml at 8 weeks was higher than that in patients with a serum ribavirin concentration <3.5 µg/ml (odds ratio =5.94); thus, the most suitable serum ribavirin concentration range 8 weeks after initiation of combination therapy was from 3 to 3.5 µg/ml (odds ratio for SVR comparing <3 µg/ml and >3 µg/ml =5.36).
In a study on genotype-1-infected patients who had undergone a dose reduction following the appearance of anaemia, Arase et al. [48] proposed that the eradication rate of serum HCV RNA could perhaps be increased by achieving a high ribavirin serum level >3 µg/ml 8 weeks after initiation of combination therapy. This concentration could be maintained at between 2 and 3 µg/ml after that; thus, as soon as ribavirin-related side effects (haemolytic anaemia) appear, it is advisable to reduce the ribavirin dose and encourage the patient not to discontinue the combination therapy. Maeda et al. [49] suggested that the optimal dosage regimen is one that enables a concentration of between 2.5 and 3.0 µg/ml.
In a study of 31 genotype-1-infected patients, Maynard et al. [50] reported that 67% of participants with plasma ribavirin concentrations >2.01 µg/ml at week 4 achieved an SVR versus only 16% of the participants with lower levels.
A recent publication by Loustaud-Ratti et al. [51] focuses on the ribavirin concentration very soon after Lastly, Tsubota et al. [52] has described the pharmacokinetics of IFN and ribavirin in 27 genotype-1-infected patients with high viral loads. For IFN, there was no correlation between the serum IFN concentration and the treatment response; however, the peak ribavirin concentration and AUC 0-12 h values of SVR patients were significantly higher than those of virological responders or non-responders. Thus, in monoinfected patients, one should aim to obtain a steady-state concentration between 3 and 3.5 µg/ml at week 8 (without exceeding 1.3 µg/ml at week 1) and thereafter maintain the value >2.5 µg/ml (Figure 1 ).
Coinfected patients
Data on this topic are scarce. In a study of 52 coinfected patients, Aguilar Marucco et al. [53] noted that a ribavirin 'trough' cutoff of 1.6 µg/ml was associated with an early virological response and an SVR; however, the term 'trough' was not clearly defined in the paper. According to the Rendón et al. study [54] of 98 coinfected patients, those who achieved an early virological response at week 4 had significantly higher plasma ribavirin levels than those who did not (3.0 versus 2.5 µg/ml, respectively).
Another study with 24 patients showed that plasma ribavirin levels during the first week of treatment were significantly lower in sustained virological responders than in non-responders [55] . The authors' hypothesis was that intracellular ribavirin accumulation early in the course of treatment might be higher in the coinfected patients who are more likely to achieve an SVR. In SVR patients, the ribavirin slope tended to increase (P=0.078) between weeks 4 and 8, in comparison with non-responders. In a study of 35 coinfected patients, Nicot et al. [56] reported that responders tended to have higher ribavirin concentrations than non-responders (2.32 versus 1.83 µg/ml, respectively). The difference was particularly obvious for genotype-1-and 4-infected patients (2.67 µg/ml for responders versus 1.76 µg/ml for non-responders).
Hence, for coinfected patients, concentrations 15% lower than those of monoinfected patients seem suitable and a steady-state concentration 0.5 µg/ml below that recommended for monoinfected patients seems appropriate (that is, approximately 2.5 µg/ml; Figure 1 ).
The relationship between dose, concentration and anaemia
The relationship between dose and anaemia
In a meta-analysis of 1,732 patients from two studies, Snoeck et al. [7] determined that the probability of anaemia increased with increasing ribavirin dose/kg, with a greater increase from approximately 15 mg/ kg/day upwards. For genotype-1-infected patients, the incidence of anaemia (defined in the Snoeck et al. [7] study as a haemoglobin level <10 g/dl) was found to be approximately 7.5% for all 48-week treatments with daily doses up to 15 mg/kg/day and almost 20% for all 48-week treatments with daily doses of >15 mg/kg/day; however, for genotype-2-and 3-infected patients, the incidence of anaemia (haemoglobin level <10 g/dl) was 3.5% for a 24-week treatment with 800 mg/day and approximately 10% for a 24-week treatment with 1,000 and 1,200 mg/day with no additional increase in the SVR.
Lindahl et al. [57] have shown that there was no apparent relationship between the relative or absolute decrease in haemoglobin and the ribavirin dose/kg, but there was a trend towards a correlation between the decrease in haemoglobin and the plasma ribavirin concentration.
The relationship between concentration and anaemia
In addition to the current study, there are more publications on the relationship between plasma or serum ribavirin concentrations and anaemia. In a study of 97 Japanese patients, Saito et al. [27] showed that the correlation between the ribavirin concentration and ∆Hb was strongest at week 1. The minimum and maximum ∆Hb were significantly correlated with the ribavirin concentration on days 7, 14 and 28 but not on day 56. Maeda et al. [49] indicated that the ∆Hb was linearly dependent on the steady-state plasma ribavirin concentration (Css) and that a haemoglobin concentration <8.5 g/dl occurred when the Css increased above 3.5 µg/ml. This concentration was confirmed by Arase et al. [8] in another study. For coinfected patients, Rendón et al. [54] calculated a 73% sensitivity and 81% sensibility for predicting a ∆Hb>2 g/dl when the ribavirin concentration was >2.8 µg/ml. According to Aguilar Marucco et al. [53] , a ribavirin trough concentration (C trough )>2.3 µg/ml was associated with a ∆Hb of >4 g/dl. Lastly, a significant correlation between RBC ribavirin concentration (but not the plasma ribavirin concentration) and ∆Hb was described by Inoue et al. [22] in 19 patients.
Supplementation and anaemia
McHutchison et al. [58] have reported that patients who were unable to adhere to full-dose therapy during the first 12 weeks of treatment had a lower SVR rate than patients who did not require dose reduction until after week 12. Shiffman et al. [59] stated that reducing the ribavirin dose to <80% or 60% of the starting dose during the first 20 weeks of treatment was associated with a decrease in the SVR rate from 21% to 11% at 72 weeks. The development of strategies to maximize adherence is an important issue in combination therapy for HCV infection.
As described above, one of the causes of haemolytic anaemia is considered to be the low RBC deformability that results from the accumulation of phosphorylated ribavirin in these cells. Eicosapentaenoic acid (EPA) has a wide variety of pharmacological actions, including the increase of RBC deformability. Hino et al. [60] observed a decrease in EPA content in RBC membrane phospholipids in HCV-infected patients on IFN plus ribavirin therapy and suggested that EPA supplementation would be useful for preventing ribavirin-induced anaemia.
Takaki et al. [61] performed a randomized trial on 100 patients on a combination therapy with a ribavirin dose of 600-1,000 mg, according to BW. The first subgroup (n=49) received EPA supplementation and the other group (n=51) did not. In total, 17% of the patients in the EPA group and 29% in the non-EPA group required ribavirin dose reduction. Of these patients, a haemoglobin level <10 g/dl occurred in 11 cases, 1 in the EPA group and 10 in the non-EPA group.
Hino et al. [60] have published a randomized study on chronic hepatitis C patients receiving the standard treatment alone or the standard treatment supplemented with a-tocopherol and ascorbic acid. They noted that supplementation attenuated the ribavirininduced decrease in EPA content in RBC membrane phospholipids. Supplementation did not prevent ribavirin-induced anaemia but tended to lower the frequency of ribavirin dose reduction (14.3% in the supplementation group and 47.1% in the standard group) and the rate of therapy discontinuance (7.1% versus 35.3%, respectively). An Italian group has studied the influence of a tomato-rich food containing an abundance of antioxidants. Only 8.7% of the patients supplemented with antioxidant-rich tomato-based functional food had to reduce their daily ribavirin dose, whereas reduction was necessary for 30.4% of patients in the nonsupplemented group [62] . Obviously, anaemia is best treated with EPO and personalized monitoring of ribavirin's adverse effect could limit the unwarranted use of EPO and optimize it when justified. Increasing evidence now supports the use of recombinant human erythropoietin, such as epoetin a, epoetin b and darbepoetin a, to manage anaemia in patients with the objective of maintaining the ribavirin dose [63] ; thus, with an aim of obtaining and maintaining optimal ribavirin concentrations, the use of EPO proves to be necessary.
Conclusions
With the development of specifically targeted anti-HCV therapies (STAT-C) and antiproteases in particular, one might think that HCV infection will soon be treated with PEG-IFN-a plus a protease or polymerase inhibitor -thereby eliminating the need for ribavirin. However, as shown in the PROVE 2 and PROVE 3 studies [64, 65] , the arm in which patients received only PEG-IFN-a and telaprevir had very high relapse rates and low SVR rates; this indicates that ribavirin is likely to remain an essential component of future treatments. In addition, a Phase II clinical trial of R1626 (the prodrug of R1479, an HCV-polymerase inhibitor) has revealed in vivo synergy between R1626 and PEG-IFN-a plus ribavirin or ribavirin aloneagain suggesting that ribavirin will remain an important initial agent as novel small molecules are added to the current standard of care [66] .
Despite the poor understanding of its mechanism of action, ribavirin remains the single most important drug in the HCV infection therapy cocktail for preventing relapse. As mentioned above, ribavirin's efficacy is greatest when concentrations are high; however, the severity of anaemia also increases with concentration. Viramidine, a prodrug of ribavirin by its hepatic specificity, could prevent this problem to an extent. A Phase III study with viramidine showed encouraging results and significantly fewer cases of anaemia [67] . It is very important to monitor the plasma ribavirin concentration until a steady state is reached. In a given individual, plasma ribavirin concentrations are quite stable over the time; therefore, once a steady state is achieved, plasma ribavirin levels can be reliably measured. However, because plasma ribavirin concentrations show great interindividual variability, it is not very easy to treat patients by simply referring to BW. In particular, a concentration of between 2.5 and 3.0 µg/ ml between weeks 4 and 8 is required to improve the SVR in genotype-1-infected patients. To avoid severe anaemia and thus discontinuation of therapy, the ribavirin concentration should not be higher than 1.3 µg/ ml at week 1 (Figure 1 ). In patients who experience a marked reduction in haemoglobin concentrations, it is important to reduce the dose of ribavirin as soon as possible to allow the safe continuation of treatment and to reduce the number of discontinuations. It must be kept in mind that the guidelines for monoinfected patients should not necessarily be extrapolated to coinfected patients, as they depend on the highly active antiretroviral therapy used. In conclusion, ribavirin monitoring must be at least considered in HCV genotype-1-infected patients and (regardless of the genotype) in obese, coinfected, renal insufficient and haemodialyzed patients.
